PT005 clinical trials
Also written PT005.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses PT005 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses PT005 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- PT003 MDI Dose Confirmation StudyCompletedPhase 2Pearl Therapeutics, Inc.NCT01349816Written as PT005
- Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy SubjectsCompletedPhase 1Pearl Therapeutics, Inc.NCT00893971Written as PT005
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2Pearl Therapeutics, Inc.NCT01085045Written as PT005 MDI
- PT003 MDI Cardiovascular Safety StudyCompletedPhase 2Pearl Therapeutics, Inc.NCT01349803Written as PT005 MDI
- Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedPhase 2Pearl Therapeutics, Inc.NCT01587079Written as PT005
- PT005 MDI Dose Ranging Versus Foradil Aerolizer StudyCompletedPhase 2Pearl Therapeutics, Inc.NCT01349868Written as PT005 MDI